This source describes a phase 3 clinical trial investigating the effectiveness of intravenous fosphenytoin for treating sudden, intense flare-ups of trigeminal neuralgia. While standard oral medications often fail to provide immediate relief for this severe facial pain, the study found that injectable therapy significantly reduced pain levels within two hours compared to a placebo. Researchers also noted a substantial decrease in the frequency of attacks over a 24-hour period among those receiving the active drug. The trial results indicate that the treatment was well-tolerated, with only mild side effects like sleepiness and nausea reported by participants. Ultimately, the authors conclude that this medication offers a promising emergency intervention for patients in crisis, though larger studies are suggested to confirm these preliminary findings. This research provides high-level evidence for a fast-acting alternative to surgery or insufficient oral drugs.
Podden och tillhörande omslagsbild på den här sidan tillhör
Amer Ghavanini. Innehållet i podden är skapat av Amer Ghavanini och inte av,
eller tillsammans med, Poddtoppen.